1,461 results match your criteria Current Oncology Reports[Journal]


Anticoagulation in Cancer Patients: a Summary of Pitfalls to Avoid.

Curr Oncol Rep 2019 Feb 4;21(2):18. Epub 2019 Feb 4.

Taussig Cancer Institute, Cleveland Clinic, 10201 Carnegie Ave./CA60, Cleveland, OH, 44195, USA.

Purpose Of Review: Venous thromboembolism (VTE) is a leading cause of morbidity and mortality in cancer patients, and its management is often associated with complications including risk of recurrent VTE and bleeding. Here, we review the current data on pitfalls during anticoagulation in cancer patients and measures necessary to avoid them.

Recent Findings: Although low-molecular-weight heparin monotherapy has been the standard of treatment for several years, emerging data for direct oral anticoagulants (DOACs) are leading to new paradigms in treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0767-5DOI Listing
February 2019
1 Read

New Treatment Options for Acute Myeloid Leukemia in 2019.

Curr Oncol Rep 2019 Feb 4;21(2):16. Epub 2019 Feb 4.

Department of Hematology, Hopital Saint-Louis, Assistance Publique Hopitaux de Paris, Paris Diderot University, Paris, France.

Purpose Of Review: The extensive genomic characterization of acute myeloid leukemia (AML) led to the identification of a vast number of potential therapeutic targets. We review relevant data that have led to recent approval of new targeted therapies in AML and discuss the most promising drugs currently in development in this disease.

Recent Findings: New formulations of cytotoxic agents, namely CPX-351 and gemtuzumab ozogamicin, improve the outcome of defined subgroup of patients. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-019-0764-8
Publisher Site
http://dx.doi.org/10.1007/s11912-019-0764-8DOI Listing
February 2019
11 Reads

Recent Development of Wnt Signaling Pathway Inhibitors for Cancer Therapeutics.

Curr Oncol Rep 2019 Feb 4;21(2):12. Epub 2019 Feb 4.

Graduate College of Biomedical Sciences, Western University of Health Sciences, Pomona, CA, 91766, USA.

Purpose Of Review: Review current understanding of both canonical and non-canonical Wnt signaling in cancer and provide updated knowledge in current clinical trials of Wnt signaling drugs.

Recent Findings: Important roles of both canonical and non-canonical Wnt signaling in cancer have been increasingly recognized. Recent clinical trials of several Wnt-signaling drugs have showed promising outcomes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0763-9DOI Listing
February 2019

BET and EZH2 Inhibitors: Novel Approaches for Targeting Cancer.

Curr Oncol Rep 2019 Feb 4;21(2):13. Epub 2019 Feb 4.

Medical Oncology, Oncology Institute of Southern Switzerland, Ospedale San Giovanni, 6500, Bellinzona, Switzerland.

Purpose Of Review: Increasing evidence suggests that epigenome plays a central role in cancer development making it a promising target for anticancer treatments. Here, we review two new classes of epigenome-targeting agents: the bromodomain and extraterminal domain proteins (BET) inhibitors and the enhancer of zeste homolog (EZH2) inhibitors.

Recent Findings: Clinical research evaluating BET and EZH2 inhibitors is still at an early stage; however, both classes of drugs have demonstrated activity among different hematologic malignancies and solid tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0762-xDOI Listing
February 2019

Communicating with Adolescents and Young Adults about Cancer-Associated Weight Loss.

Curr Oncol Rep 2019 Feb 4;21(2):15. Epub 2019 Feb 4.

School of Medicine, Geelong Waurn Ponds Campus, Locked Bag 20000, Geelong, VIC, 3220, Australia.

Purpose Of Review: Over the past two decades, advances have been made in understanding the pathophysiology of cancer-associated weight loss, termed "cachexia." To date, there is no proven effective intervention to completely reverse cachexia and there are no approved drug therapies to treat it. This paper will review relevant literature in relation to communicating with adolescents and young adults about cancer-associated weight loss. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0765-7DOI Listing
February 2019

Bispecific Antibodies in Hematologic Malignancies: When, to Whom, and How Should Be Best Used?

Curr Oncol Rep 2019 Feb 4;21(2):17. Epub 2019 Feb 4.

Department of Hematology and Oncology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Avenida Vasco de Quiroga No. 15, Belisario Dominguez Sección XVI, Tlalpan, 14080, Mexico City, Mexico.

Purpose Of Review: The purpose of this review is to discuss the current recommendations for the use of bispecific antibodies (bsAb) in hematologic malignancies and explore the future in this field.

Recent Findings: Bispecific antibodies are molecules able to target two different antigen-binding sites: one towards a tumor antigen and another to activate a cytotoxic cell. Phase II/III trials on blinatumomab for acute lymphoblastic leukemia (ALL) have demonstrated its efficacy for treating minimal residual disease (MRD+) and relapsed refractory (r/r) Philadelphia positive (Ph+) and negative (Ph-) ALL in adults and children. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-019-0759-5
Publisher Site
http://dx.doi.org/10.1007/s11912-019-0759-5DOI Listing
February 2019
4 Reads

TRK Inhibitors: Clinical Development of Larotrectinib.

Curr Oncol Rep 2019 Feb 4;21(2):14. Epub 2019 Feb 4.

Scripps Clinic, Division of Hematology-Oncology, 10666 North Torrey Pines Road, La Jolla, CA, 92037, USA.

Purpose Of Review: In this review, we highlight the pre-clinical development, recent clinical studies, and future directions of larotrectinib in patients with NTRK fusion-positive tumors.

Recent Findings: The tropomyosin receptor kinase family, TrkA, TrkB, and TrkC, transmit extracellular signals via a variety of intracellular pathways to promote normal neuronal development. TrkA, B, and C are encoded by NTRK1, 2, and 3, respectively. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0761-yDOI Listing
February 2019
1 Read

Novel Approaches for Treating Pain in Children.

Authors:
William Splinter

Curr Oncol Rep 2019 Feb 4;21(2):11. Epub 2019 Feb 4.

Palliative Medicine, Children's Hospital of Eastern Ontario, 401 Smyth Road, Ottawa, Ontario, K1H 8L1, Canada.

Purpose Of Review: Good pain management in children, especially those at end of life, is a crucial component of palliative medicine. The current review assesses some of the new and/or innovative ways to manage pain in children. The article focuses on some recent medications/pharmaceutical options such as cannabinoids and also innovative ways to administer medication to children, such as intranasal and inhalation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0766-6DOI Listing
February 2019

A Comprehensive Review of Cannabis in Patients with Cancer: Availability in the USA, General Efficacy, and Safety.

Curr Oncol Rep 2019 Feb 1;21(1):10. Epub 2019 Feb 1.

Park Nicollet Oncology Research, HealthPartners Institute, Frauenshuh Cancer Center, 3800 Park Nicollet Blvd, Minneapolis, MN, 55416, USA.

Purpose Of Review: As the legalization of medical cannabis continues across the USA, oncology care providers will be increasingly asked to provide recommendations regarding its use in the cancer setting. In this article, we review recent literature that analyzes cannabis use specifically in patients with cancer and provide an accessible guide for clinicians, researchers, and patients.

Recent Findings: We aimed to answer questions about the availability of cannabis in the USA, the trials supporting its use in the cancer setting, and the important factors to consider related to safety. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0757-7DOI Listing
February 2019

Changing Hearts and Minds: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity.

Curr Oncol Rep 2019 Jan 30;21(1). Epub 2019 Jan 30.

Division of Cancer Prevention, National Cancer Institute, Rockville, MD, USA.

Purpose Of Review: Cardiovascular effects from cancer treatment remains a leading cause of treatment-associated morbidity and mortality among cancer survivors. The National Cancer Institute and National Heart, Lung, and Blood Institute convened a Workshop in June 2018 entitled "Changing Hearts and Minds: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity" to highlight progress, ongoing work, and update scientific priorities since the 2013 Workshop. Here we will describe these advances and provide an overview of the research priorities identified. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0751-0DOI Listing
January 2019

Plasma Cell Leukemia: Definition, Presentation, and Treatment.

Curr Oncol Rep 2019 Jan 28;21(1). Epub 2019 Jan 28.

Department of Hematology, Odense University Hospital, Kloevervaenget 10, 12th floor, DK-5000, Odense C, Denmark.

Purpose Of Review: We discuss current topics on the definition of plasma cell leukemia and the distinction between plasma cell leukemia and multiple myeloma. Moreover, we review the latest literature on how to treat plasma cell leukemia.

Recent Findings: Plasma cell leukemia is clinically and genetically distinct from multiple myeloma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0754-xDOI Listing
January 2019

On Heartbreak in Oncology.

Authors:
Daniel Rayson

Curr Oncol Rep 2019 Jan 25;21(1). Epub 2019 Jan 25.

Division of Medical Oncology, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Room 457A Bethune Building, 1276 South Park St., B3H2Y9, Halifax, Nova Scotia, Canada.

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-019-0755-9
Publisher Site
http://dx.doi.org/10.1007/s11912-019-0755-9DOI Listing
January 2019
2 Reads

HIF Inhibitors: Status of Current Clinical Development.

Curr Oncol Rep 2019 Jan 22;21(1). Epub 2019 Jan 22.

Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Desk CA60, Cleveland, OH, 44195, USA.

Purpose Of Review: In this review, the importance of the hypoxia inducible factor (HIF) pathway in tumorigenesis and cancer treatment outcomes will be discussed. The outcomes of phase II and III clinical trials of direct HIF inhibitors in the treatment of cancer will be reviewed.

Recent Findings: The HIF signaling pathway is activated by tumor-induced hypoxia or by inactivating mutations of the VHL gene. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0752-zDOI Listing
January 2019
4 Reads

Management of Residual Mass in Germ Cell Tumors After Chemotherapy.

Curr Oncol Rep 2019 Jan 21;21(1). Epub 2019 Jan 21.

Department of Urology, Indiana University School of Medicine, 535 Barnhill Dr., Indianapolis, IN, 46202, USA.

Purpose Of Review: The purpose of this review is to educate medical oncologists on the management of patients with residual germ cell tumors and the role of surgical resection after platinum-based chemotherapy.

Recent Findings: Patients with non-seminomatous testicular cancer and residual enlarged retroperitoneal lymph nodes > 1 cm following induction chemotherapy with normal tumor markers should undergo a post-chemotherapy retroperitoneal lymph node dissection. All patients with primary mediastinal non-seminoma should undergo surgical resection of the mediastinal mass post-chemotherapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0758-6DOI Listing
January 2019
2 Reads

Cytokine Release Syndrome With the Novel Treatments of Acute Lymphoblastic Leukemia: Pathophysiology, Prevention, and Treatment.

Curr Oncol Rep 2019 Jan 21;21(1). Epub 2019 Jan 21.

Gehr Family Center for Leukemia Research, City of Hope, 1500 Duarte Rd, Duarte, CA, 91010, USA.

Purpose Of Review: T cell-based therapies (blinatumomab and CAR T cell therapy) have produced unprecedented responses in relapsed and refractory (r/r) acute lymphoblastic leukemia (ALL) but is accompanied with significant toxicities, of which one of the most common and serious is cytokine release syndrome (CRS). Here we will review the pathophysiology, prevention, and treatment of CRS.

Recent Findings: Efforts have been initiated to define and grade cytokine release syndrome (CRS), to identify patients at risk, to describe biomarkers that predict onset and severity, to understand the pathophysiology, and to prevent and treat severe cases to reduce T cell immunotherapy-related morbidity and mortality. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0753-yDOI Listing
January 2019

Indoleamine Dioxygenase Inhibitors: Clinical Rationale and Current Development.

Curr Oncol Rep 2019 Jan 18;21(1). Epub 2019 Jan 18.

Genetic Pathology Evaluation Centre, Department of Pathology & Laboratory Medicine, University of British Columbia, 509-3660 Oak St, Vancouver, BC, V5Z 1M9, Canada.

Purpose Of Review: This review focuses on the recent clinical development of indolamine-2,3-dioxygenase-1 (IDO-1) inhibitors.

Recent Findings: IDO-1 alters tryptophan metabolism in a manner enhancing T-regulatory cell activity, but pre-clinical data show that its role in tumorigenesis is context-dependent on host and tumor interaction, highlighting some challenges in understanding the molecular oncology of this enzymatic drug target. Because results from phase I/II trials of IDO-1 inhibitor monotherapy have been disappointing, current clinical trials employ IDO-1 inhibitors in combination strategies with other immunotherapy agents or with chemotherapy ± radiation. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-019-0750-1
Publisher Site
http://dx.doi.org/10.1007/s11912-019-0750-1DOI Listing
January 2019
3 Reads

Colon Cancer in Young Adults: Trends and Their Implications.

Curr Oncol Rep 2019 Jan 18;21(1). Epub 2019 Jan 18.

Ruesch Center for the Cure of Gastrointestinal Cancers, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, 3800 Reservoir Road NW, Washington, D.C, 20007, USA.

Purpose Of Review: The recent rise of young individuals under age 50 with colorectal cancer (CRC) is a startling trend in need of greater focus and research. The etiology of young-onset CRC is unexplained as efforts to blame obesity or diabetes as causative factors are simplistic and inadequate.

Recent Findings: We describe the epidemiologic shifts of CRC incidence and mortality across age groups as well as the differences in clinicopathologic, molecular, treatment, and survival characteristics between young and older patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-019-0756-8DOI Listing
January 2019
5 Reads

Transformation of Old Concepts for a New Era of Cancer Immunotherapy: Cytokine Therapy and Cancer Vaccines as Combination Partners of PD1/PD-L1 Inhibitors.

Curr Oncol Rep 2018 Nov 15;21(1). Epub 2018 Nov 15.

Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Dana 2127, Boston, MA, 02215, USA.

Purpose Of Review: Immune checkpoint inhibitors (ICI) are only effective in a subset of patients. Here, we will review the rationale and data supporting the combination of PD-1 pathway inhibition with recombinant cytokines and neoantigen-based cancer vaccines that can potentially increase the number of patients who will benefit from immunotherapy.

Recent Findings: The safety and tolerability of new interleukin(IL)-2 formulations, IL-15 super agonist, and PEGylated IL-10 have been evaluated in early phase clinical trials with promising efficacy data, both as monotherapy and in combination with ICI. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-018-0738-2DOI Listing
November 2018
3 Reads

Anti-CD20 Directed Therapy of B Cell Lymphomas: Are New Agents Really Better?

Curr Oncol Rep 2018 Nov 27;20(12):103. Epub 2018 Nov 27.

BC Cancer, 600 W 10th Avenue, Vancouver, BC, Canada.

Purpose Of Review: Since its initial approval in 1997, rituximab has revolutionized the treatment of CD20-positive lymphoproliferative disorders. Now, over two decades later, second-generation molecules are emerging that may have key biological advantages compared to rituximab, as well as biosimilars that may be more cost-effective. Clinicians, health policy makers, and payers will now need to critically appraise the available evidence for these competitors and decide which anti-CD20 to use. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-018-0748-0DOI Listing
November 2018
2 Reads

Treatment of Rectal Cancer in Older Adults.

Curr Oncol Rep 2018 Nov 20;20(12):102. Epub 2018 Nov 20.

Section of Hematology/Oncology, Boston University Medical Center, FGH building, 1st floor, 820 Harrison Avenue, Boston, MA, 02118, USA.

Purpose Of Review: Rectal cancer is predominantly a disease of older adults but current guidelines do not incorporate the associated specific challenges leading to wide variation in the delivery of cancer care to this subset of population. Here, we will review the current data available regarding the management of rectal cancer in older adults.

Recent Findings: The greatest challenge arises in the management of stage II/III disease as it involves tri-modality treatment that can be harder to tolerate by frail older patients. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-018-0746-2
Publisher Site
http://dx.doi.org/10.1007/s11912-018-0746-2DOI Listing
November 2018
15 Reads

Correction to: The Role of Oncolytic Viruses in the Treatment of Melanoma.

Curr Oncol Rep 2018 Nov 13;20(12):100. Epub 2018 Nov 13.

Department of Medicine, Division of Hematology/Oncology, Columbia University Medical Center, 161 Fort Washington Avenue, New York, NY, 10032, USA.

A correction was made to a sentence in the original article to provide additional clarification in the "Other Oncolytic Viruses" section. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-018-0749-z
Publisher Site
http://dx.doi.org/10.1007/s11912-018-0749-zDOI Listing
November 2018
5 Reads
2.891 Impact Factor

Prevention Strategies in Endometrial Carcinoma.

Curr Oncol Rep 2018 Nov 13;20(12):101. Epub 2018 Nov 13.

Department of Obstetrics and Gynaecology, St Mary's Hospital, Manchester Academic Health Science Centre, Manchester University NHS Foundation Trust, Manchester, UK.

Purpose Of The Review: To assess the most recent high-quality evidence for endometrial cancer prevention strategies.

Recent Findings: Obesity is an established risk factor for endometrial cancer. Weight cycling and weight gain in middle age are risk factors for endometrial cancer. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-018-0747-1
Publisher Site
http://dx.doi.org/10.1007/s11912-018-0747-1DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244901PMC
November 2018
11 Reads

Management of Locally Advanced and Metastatic Esophageal Cancer in the Older Population.

Curr Oncol Rep 2018 Nov 13;20(12):99. Epub 2018 Nov 13.

Medical Oncology Department, University Hospital Waterford, Dunmore Road, Waterford, X91 ER8E, Ireland.

Purpose Of Review: This review aims to synthesise the current literature on the management of early-stage and metastatic esophageal cancers, focusing on the older population. In particular, we aim to dissect out the elderly-specific data from the relevant trials and to discuss the issues unique to this population.

Recent Findings: While surgery is the curative modality in esophageal malignancies, the CROSS, MAGIC and FLOT trials demonstrate a clear advantage to neoadjuvant therapy (chemotherapy and chemoradiotherapy). Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-018-0745-3
Publisher Site
http://dx.doi.org/10.1007/s11912-018-0745-3DOI Listing
November 2018
11 Reads

The Role of Hypnosis in Cancer Care.

Curr Oncol Rep 2018 Nov 13;20(12):93. Epub 2018 Nov 13.

Department of Oncology, Cumming School of Medicine, Psychosocial Resources, University of Calgary, 2202 2nd St SW, Calgary, AB, T2S 3C1, Canada.

Purpose Of Review: This paper reviews the current evidence-base for the use of hypnosis as an adjunct treatment for common cancer-related symptoms and side effects, including those experienced during treatment, as well as long-term and late effects. First, a general description and history of medical hypnosis in cancer care is provided, followed by a review of the latest evidence across a range of common symptoms.

Recent Findings: The evidence suggests that hypnosis may help treat symptoms of nausea and vomiting in breast cancer patients, manage pain in a variety of contexts, and also reduce levels of anxiety and overall distress around surgical and medical procedures, both in children and adults. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-018-0739-1
Publisher Site
http://dx.doi.org/10.1007/s11912-018-0739-1DOI Listing
November 2018
8 Reads

Surgical Management of Lung Cancer: History, Evolution, and Modern Advances.

Authors:
Abbas E Abbas

Curr Oncol Rep 2018 Nov 13;20(12):98. Epub 2018 Nov 13.

Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine, Fox Chase Cancer Center and Temple University Hospital, 3401 N. Broad St., Suite C-100, Philadelphia, PA, 19140, USA.

Purpose Of Review: Although surgery for lung cancer was not common before the early twentieth century, it has enjoyed remarkable progress since then both in type of resection and technical approach. This has been coupled with significant technological advances. Here, we will review the history and evolution of this relatively new field of surgery. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-018-0741-7
Publisher Site
http://dx.doi.org/10.1007/s11912-018-0741-7DOI Listing
November 2018
11 Reads

Palliative Care in Patients with Leukemia: When and How?

Curr Oncol Rep 2018 Nov 13;20(12):95. Epub 2018 Nov 13.

Palliative, Rehabilitation and Integrative Medicine, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1414, Houston, TX, 77034, USA.

Purpose Of Review: Patients with hematologic malignancies get more aggressive treatment and the end-of-life, more ICU deaths, and prolonged hospital stays. In comparison to solid tumors, their access to palliative care and hospice is less.

Recent Findings: Multiple factors seem to play a role including curative goals, different treatment options, stronger relationship between patients and oncologist, symptom burden, and limitations of hospice care. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-018-0743-5
Publisher Site
http://dx.doi.org/10.1007/s11912-018-0743-5DOI Listing
November 2018
23 Reads

Practical Strategies for Optimizing and Integrating Palliative Care in Cancer.

Curr Oncol Rep 2018 Nov 13;20(12):97. Epub 2018 Nov 13.

Duke University Health, 20 Medicine Circle, Box 2715, Durham, NC, 27710, USA.

Purpose Of Review: Recent reforms in medical payment coupled with a rapidly evolving pharmacotherapeutic armamentarium is creating a transition in the field of oncology. This transition represents a key period for conceptual reevaluation, providing an opportunity for furthered strategic integration of palliative care within the realm of oncology.

Recent Findings: Historically, oncologists have relied upon prognostic assessments to gauge appropriateness for referrals to specialty palliative care. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-018-0742-6
Publisher Site
http://dx.doi.org/10.1007/s11912-018-0742-6DOI Listing
November 2018
9 Reads

Where Are We Going with Sentinel Lymph Node Mapping in Gynecologic Cancers?

Curr Oncol Rep 2018 Nov 13;20(12):96. Epub 2018 Nov 13.

The Kelly Gynecologic Oncology Service, Johns Hopkins Hospital, 600 N Wolfe St. Phipps 281, Baltimore, MD, 21287, USA.

Purpose Of Review: Sentinel lymph node (SLN) mapping is a standard of care for lymphatic assessment of many early-stage gynecologic malignancies. We review the current data, emphasizing the utility of SLN mapping in the management of gynecologic cancers.

Recent Findings: Endometrial cancer: recent studies have focused on confirming the safety and efficacy of SLN mapping for high-risk patients. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-018-0744-4
Publisher Site
http://dx.doi.org/10.1007/s11912-018-0744-4DOI Listing
November 2018
16 Reads

Combination Immune Checkpoint Blockade Strategies to Maximize Immune Response in Gynecological Cancers.

Curr Oncol Rep 2018 Nov 13;20(12):94. Epub 2018 Nov 13.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

Purpose Of Review: Immune checkpoint blockade targeting PD-1 and PD-L1 improves immune recognition of tumor cells but had only modest success in gynecological cancers as monotherapy. Growing focus has been placed on combination immunotherapy strategies to overcome this resistance, and this review serves to discuss some of the most promising studies in gynecological cancers.

Recent Findings: PD-1- and PD-L1-targeting antibodies are being combined with many novel agents including anti-CTLA-4 antibodies, PARP inhibitors, targeted agents, and traditional chemotherapy in promising studies with the hopes of increasing the immune response and overcoming resistance by targeting other pathways. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-018-0740-8
Publisher Site
http://dx.doi.org/10.1007/s11912-018-0740-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6244932PMC
November 2018
9 Reads

Updates in the Diagnosis and Treatment of Paraneoplastic Neurologic Syndromes.

Curr Oncol Rep 2018 Nov 10;20(11):92. Epub 2018 Nov 10.

Neurology Division, Hospital das Clínicas, University of São Paulo School of Medicine, Sao Paulo, Brazil.

The disorders of the central nervous system associated with cancer by remote immune-mediated mechanisms are a heterogeneous group. These disorders encompass the classic paraneoplastic disorders and the recently recognized autoimmune encephalitis associated with antibodies against neuronal cell surface or synaptic proteins that occur with or without cancer association. In the last decade, the new surge of interest in neuronal diseases associated with anti-neuronal antibodies led to the rapid discovery of new forms of disease that have different manifestations and were not previously suspected to be immune mediated. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-018-0721-y
Publisher Site
http://dx.doi.org/10.1007/s11912-018-0721-yDOI Listing
November 2018
12 Reads

Palliative Care in Lung Cancer: When to Start.

Curr Oncol Rep 2018 Nov 9;20(11):90. Epub 2018 Nov 9.

Lankenau Cancer Center, PA, Wynnewood, USA.

Purpose Of Review: Despite recent advances in the care of patients with advanced non-small cell lung cancer (NSCLC), significant morbidity and mortality remains. Symptoms caused by the cancer and its treatments can be profoundly debilitating. Palliative care aims to reduce this burden. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-018-0731-9
Publisher Site
http://dx.doi.org/10.1007/s11912-018-0731-9DOI Listing
November 2018
16 Reads

Pseudoprogression of Melanoma Brain Metastases.

Curr Oncol Rep 2018 Nov 9;20(11):91. Epub 2018 Nov 9.

Northwestern University Feinberg School of Medicine, 645 N Michigan Ave, Suite 1006, Chicago, IL, 60611, USA.

Purpose Of Review: Immune checkpoint inhibitors are increasingly being used to treat melanoma brain metastases. One potential complication of immune checkpoint inhibitors is a phenomenon called pseudoprogression, in which a tumor transiently increases in size due to lymphocyte infiltration. This article reviews the characteristics of pseudoprogression and their clinical implications. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-018-0722-x
Publisher Site
http://dx.doi.org/10.1007/s11912-018-0722-xDOI Listing
November 2018
16 Reads

Molecular Mechanisms of Cisplatin Chemoresistance and Its Circumventing in Testicular Germ Cell Tumors.

Curr Oncol Rep 2018 Sep 26;20(11):88. Epub 2018 Sep 26.

Cancer Research Institute, Biomedical Research Center, Slovak Academy of Sciences, Dúbravská cesta 9, 845 05, Bratislava, Slovakia.

Purpose Of Review: Testicular germ cell tumors (TGCTs) represent the most common solid tumors affecting young men. Majority of TGCTs respond well to cisplatin-based chemotherapy. However, patients with refractory disease have limited treatment modalities associated with poor prognosis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-018-0730-xDOI Listing
September 2018
4 Reads

How Intraoperative Tools and Techniques Have Changed the Approach to Brain Tumor Surgery.

Curr Oncol Rep 2018 Sep 26;20(11):89. Epub 2018 Sep 26.

Department of Neurosurgery, Stanford University, 300 Pasteur Dr, Stanford, CA, 94305, USA.

Purpose Of Review: Surgical treatment of brain tumors remains an integral part of a comprehensive treatment plan. Here, we review technological advances that have enhanced what surgeons are capable of doing within and outside the traditional operating room.

Recent Findings: Extent of surgical resection has improved with the use of MRI and fluorescent dyes intraoperatively. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-018-0723-9
Publisher Site
http://dx.doi.org/10.1007/s11912-018-0723-9DOI Listing
September 2018
5 Reads

The World of Melanoma: Epidemiologic, Genetic, and Anatomic Differences of Melanoma Across the Globe.

Curr Oncol Rep 2018 Sep 24;20(11):87. Epub 2018 Sep 24.

Department of Dermatology, University Hospital Zurich, Gloriastrasse 31, 8091, Zurich, Switzerland.

Purpose Of Review: As cancer remains an increasing problem in industrial countries, the incidence of melanoma has risen rapidly in many populations during the last decades and still continues to rise. Current strategies aiming to control the disease have largely focused on improving the understanding of the interplay of causal factors for this cancer.

Recent Findings: Cutaneous melanoma shows clear differences in incidence, mortality, genomic profile, and anatomic presentation, depending on the country of residence, ethnicity, and socioeconomic status. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-018-0732-8
Publisher Site
http://dx.doi.org/10.1007/s11912-018-0732-8DOI Listing
September 2018
3 Reads

Molecular Pathways in Melanomagenesis: What We Learned from Next-Generation Sequencing Approaches.

Curr Oncol Rep 2018 Sep 14;20(11):86. Epub 2018 Sep 14.

Institute of Pathology, Azienda Ospedaliero Universitaria (AOU), Sassari, Italy.

Purpose Of Review: Conventional clinico-pathological features in melanoma patients should be integrated with new molecular diagnostic, predictive, and prognostic factors coming from the expanding genomic profiles. Cutaneous melanoma (CM), even differing in biological behavior according to sun-exposure levels on the skin areas where it arises, is molecularly heterogeneous. The next-generation sequencing (NGS) approaches are providing data on mutation landscapes in driver genes that may account for distinct pathogenetic mechanisms and pathways. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-018-0733-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6153571PMC
September 2018
1 Read

Cancer in Sexual and Gender Minority Patients: Are We Addressing Their Needs?

Curr Oncol Rep 2018 Sep 13;20(11):85. Epub 2018 Sep 13.

Department of Oncology, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA.

Purpose Of Review: To describe the current literature regarding the cancer care of sexual and gender minority patients and to identify significant knowledge gaps that hinder our understanding of the unique needs of sexual and gender minority patients with cancer.

Recent Findings: Sexual and gender minorities suffer from cancer-related disparities, including lower rates of cancer screening, higher incidence of certain cancers, and higher cancer mortality rates. Sexual side effects, depression, and social isolation are especially common among sexual minority individuals with cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-018-0737-3DOI Listing
September 2018
1 Read

The Role of the Specialist Nurse in Gynaecological Cancer.

Curr Oncol Rep 2018 Sep 11;20(10):83. Epub 2018 Sep 11.

Hull and East Yorkshire Hospitals NHS Trust, Hull Royal Infirmary, Hull, UK.

Purpose Of Review: To explore the role of the specialist nurse within gynaecological cancer.

Recent Findings: There are many different job titles associated with the role of the specialist nurse. Nursing roles are evolving not only to meet the increasing demands on services but also within the ever changing landscape of cancer treatments and improvement in survival. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-018-0734-6
Publisher Site
http://dx.doi.org/10.1007/s11912-018-0734-6DOI Listing
September 2018
9 Reads

Radioactive Iodine-Refractory Differentiated Thyroid Cancer in the Elderly.

Curr Oncol Rep 2018 Sep 11;20(10):82. Epub 2018 Sep 11.

Sylvester Comprehensive Cancer Center, University of Miami - Miller School of Medicine, Miami, FL, USA.

Most common thyroid cancers are differentiated thyroid cancers (DTCs) and have papillary, follicular, or Hürthle cell morphology. Papillary thyroid carcinoma (PTC) is the most common malignant tumor of the thyroid gland. The incidence of DTC increases with age. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-018-0736-4
Publisher Site
http://dx.doi.org/10.1007/s11912-018-0736-4DOI Listing
September 2018
17 Reads

Evaluating the Use of 18F-FDG PET CT for External Beam Radiotherapy Planning in Gynaecological Malignancies.

Curr Oncol Rep 2018 Sep 11;20(10):84. Epub 2018 Sep 11.

Beatson West of Scotland Cancer Centre, Gartnavel General Hospital, Glasgow, G12 0YN, UK.

Purpose Of Review: To evaluate the evidence for the use of fluorine-18-fluorodeoyglucose (18F-FDG) PET CT in external beam radiotherapy planning for treatment of gynaecological malignancies.

Recent Findings: Our review confirms that the incorporation of 18F-FDG PET CT during radiotherapy planning may decrease inter-observer variability during target delineation. It can also provide useful functional information regarding the tumour, which may facilitate the development of techniques for dose escalation and 'dose painting' not only for primary disease, especially in cervical cancer, but also nodal metastasis. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-018-0735-5
Publisher Site
http://dx.doi.org/10.1007/s11912-018-0735-5DOI Listing
September 2018
7 Reads

Building a Cardio-Onco-Hematology Program.

Curr Oncol Rep 2018 Sep 10;20(10):81. Epub 2018 Sep 10.

Department of Oncology, Mayo Clinic, Rochester, MN, USA.

Purpose Of Review: This review aims to outline the general principles of how to build a cardio-onco-hematology clinic, acknowledging that there are diverse practices ranging from private community settings to academic hospitals and each practice environment has to build its own program.

Recent Findings: The refinement of regimens and introduction of molecularly directed therapies have substantially increased survival rates for patients with cancer. In fact, a number of previous imminently fatal malignant disease processes have been turned into chronic diseases, such that patients now live with certain incurable cancers as they do, for instance, with rheumatoid arthritis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-018-0725-7DOI Listing
September 2018
3 Reads

The Role of Oncolytic Viruses in the Treatment of Melanoma.

Curr Oncol Rep 2018 Aug 25;20(10):80. Epub 2018 Aug 25.

Department of Medicine, Division of Hematology/Oncology, Columbia University Medical Center, 161 Fort Washington Avenue, New York, NY, 10032, USA.

Purpose Of Review: Oncolytic virotherapy is a new approach to the treatment of cancer and its success in the treatment of melanoma represents a breakthrough in cancer therapeutics. This paper provides a review of the current literature on the use of oncolytic viruses (OVs) in the treatment of melanoma.

Recent Findings: Talimogene laherparepvec (T-VEC) is the first OV approved for the treatment of melanoma and presents new challenges as it enters the clinical setting. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-018-0729-3
Publisher Site
http://dx.doi.org/10.1007/s11912-018-0729-3DOI Listing
August 2018
21 Reads
2.891 Impact Factor

Acute Coronary Syndrome Management in Cancer Patients.

Curr Oncol Rep 2018 Aug 22;20(10):78. Epub 2018 Aug 22.

Florida Hospital, Pepin Heart Institute, 3100 E Fletcher Ave, Tampa, FL, 33613, USA.

Purpose Of Review: Coronary artery disease and cancer often co-exist. Patients with cancer have been excluded by most major cardiology trials and registries and their management remains largely empiric. Cancer patients experience an approximately 10-times increased mortality compared to the general population. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-018-0724-8DOI Listing
August 2018
3 Reads

Toward a Risk-Tailored Therapeutic Policy in Mantle Cell Lymphoma.

Curr Oncol Rep 2018 Aug 22;20(10):79. Epub 2018 Aug 22.

Institute of Oncology Research (IOR), Via Vela 6, 6500, Bellinzona, Switzerland.

Purpose Of Review: Mantle cell lymphoma (MCL) prognosis is strictly related to the characteristics of the disease, which can range from very indolent cases to highly aggressive and refractory ones. Here we will review the current knowledge on MCL biomarkers.

Recent Findings: Biomarker-informed diagnosis is essential for differentiating MCL from other mature B cell tumors. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-018-0728-4DOI Listing
August 2018
20 Reads

Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs.

Curr Oncol Rep 2018 Aug 20;20(10):76. Epub 2018 Aug 20.

Division of Medical Oncology, Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, II Policlinico via S. Pansini, 5, 80131, Naples, Italy.

Purpose Of Review: Triple-negative breast cancer (TNBC) accounts for 15-20% of diagnosed breast tumours, with higher incidence in young and African-American women, and it is frequently associated with BRCA germline mutations. Chemotherapy is the only well-established therapeutic option in both early- and advanced-stages of the disease. TNBC tumours relapse earlier after standard anthracycline- and/or taxane-based chemotherapy treatments, generally within 1-3 years after the diagnosis, and often develop visceral metastases, representing the subtype with a worse prognosis among all breast cancers. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-018-0726-6
Publisher Site
http://dx.doi.org/10.1007/s11912-018-0726-6DOI Listing
August 2018
18 Reads

Molecular Subtypes of Bladder Cancer.

Curr Oncol Rep 2018 Aug 20;20(10):77. Epub 2018 Aug 20.

Johns Hopkins Greenberg Bladder Cancer Institute and Brady Urological Institute, Johns Hopkins University, Marburg 149, 600 North Wolfe Street, Baltimore, MD, 21287, USA.

Purpose Of Review: Recent whole genome characterizations of primary human bladder cancers revealed that they can be grouped into "intrinsic" basal and luminal molecular subtypes. Here, we provide an overview of the subtypes and discuss their biological and clinical properties.

Recent Findings: Basal cancers are characterized by advanced stage and metastatic disease at presentation. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-018-0727-5DOI Listing
August 2018
5 Reads

Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks.

Curr Oncol Rep 2018 Aug 18;20(9):75. Epub 2018 Aug 18.

Division of Hematology/Oncology, NewYork-Presbyterian/Columbia University Medical Center, 177 Fort Washington Avenue, 6GN-435, New York, NY, 10032, USA.

Immunotherapy is rapidly transforming cancer care across a range of tumor types. Although Sipuleucel-T represented the first successful vaccine for the treatment of established cancer, other immunotherapeutic approaches for prostate cancer such as checkpoint inhibitors have been relatively disappointing to date. However, significant promise is on the horizon as there is a wide array trials evaluating immunotherapy in prostate cancer patients. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-018-0712-z
Publisher Site
http://dx.doi.org/10.1007/s11912-018-0712-zDOI Listing
August 2018
13 Reads

Long-term Effects of Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Patients with Acute Lymphoblastic Leukemia.

Curr Oncol Rep 2018 Aug 3;20(9):74. Epub 2018 Aug 3.

Department of Pediatrics University Vienna, St. Anna Children's Hospital, Kinderspitalgasse 6, 1090, Vienna, Austria.

Purpose Of Review: Allogeneic hematopoetic stem cell transplantation (HSCT) is a curative option for children and adolescents with high-risk leukemia. Although acute complications were reduced during the last decade, considerable late effects are still limiting the overall success rate. This article emphasizes the specific pediatric aspects of long-term aftercare following myeloablative HSCT and provides an organ-based overview that covers main clinical patterns, incidence, and risk factors enhanced by current references and screening guidelines. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-018-0719-5
Publisher Site
http://dx.doi.org/10.1007/s11912-018-0719-5DOI Listing
August 2018
4 Reads

Adoptive Cell Therapy in Treating Pediatric Solid Tumors.

Curr Oncol Rep 2018 Aug 1;20(9):73. Epub 2018 Aug 1.

Department of Pediatrics, Hematology Oncology, and Lineberger Comprehensive Cancer Center, University of North Carolina, 125 Mason Farm Road, 5203 Marsico Hall, Chapel Hill, NC, 27599-7290, USA.

Purpose Of Review: This review will discuss the challenges facing adoptive cell techniques in the treatment of solid tumors and examine the therapies that are in development for specifically pediatric solid tumors.

Recent Findings: Targeting solid tumors with adoptive cell therapy has been limited by the inhibitory tumor microenvironment and heterogeneous expression of targetable antigens. Many creative strategies to overcome these limitations are being developed but still need to be tested clinically. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11912-018-0715-9DOI Listing
August 2018
1 Read

Immune Checkpoint Inhibitor Toxicity.

Curr Oncol Rep 2018 Jul 31;20(9):72. Epub 2018 Jul 31.

Crown Princess Mary Cancer Centre, Westmead Hospital, Corner Hawkesbury & Darcy Roads, Westmead, NSW, 2145, Australia.

Purpose Of Review: Immune checkpoint inhibitors have revolutionised the treatment of multiple malignancies and have a growing list of indications. As our familiarity with these agents grows, so does our understanding of their unique spectrum of toxicities. Here, we will review the literature regarding the toxicities of checkpoint inhibitors and address challenges encountered in day-to-day clinical practice. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11912-018-0718-6
Publisher Site
http://dx.doi.org/10.1007/s11912-018-0718-6DOI Listing
July 2018
8 Reads